hero section gradient
15 handpicked stocks

Potential Bargains

These companies are trading below what experts believe they're truly worth. Our analysts have carefully selected stocks with significant upside potential, representing hidden opportunities for growth as they move toward their projected valuations.

Author avatar

Han Tan | Market Analyst

Published on June 17

Your Basket's Financial Footprint

Concise market capitalisation summary and investor key takeaways for the 'Potential Bargains' basket.

Key Takeaways for Investors:
  • Large-cap dominance implies likely lower volatility, more stable returns, and closer market-tracking than small-cap-heavy baskets.
  • Suitable as a core holding for steady exposure, not a speculative growth allocation.
  • Likely gradual, long-term appreciation rather than short-term explosive gains; manage expectations accordingly.
Total Market Cap
  • PMN: $23.69M

  • STRR: $6.89M

  • SVCO: $182.29M

  • Other

About This Group of Stocks

1

Our Expert Thinking

This collection captures the essence of value investing—buying quality assets at a discount to their intrinsic value. We've identified companies where there's a substantial gap between current price and analyst targets, suggesting significant growth potential as the market eventually recognizes their true worth.

2

What You Need to Know

These stocks come from diverse sectors including technology, biotechnology, and cyclical industries that may be temporarily out of favor. While they offer higher-reward opportunities, they can also carry more risk as the market may take time to recognize their potential value.

3

Why These Stocks

Each company was selected based on strong analyst "Buy" ratings and a substantial difference between current trading price and future valuation estimates. They represent businesses with strong fundamentals that financial experts believe the market has overlooked or undervalued.

Why You'll Want to Watch These Stocks

💰

Hidden Value Waiting to Be Discovered

These companies are flying under the radar with strong fundamentals that the market hasn't fully recognized yet. Getting in now could mean significant returns when others finally catch on.

📈

Potential for Dramatic Price Corrections

When undervalued stocks finally get the attention they deserve, price movements can happen quickly. Analysts believe these companies could see substantial growth as they move toward their true valuations.

🧠

Expert-Backed Opportunities

These aren't random picks—each stock has been identified by market professionals as trading below its intrinsic value, giving you confidence that you're investing based on expert analysis.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Global Infrastructure Partners: UAE Exposure Risks

Global Infrastructure Partners: UAE Exposure Risks

The UAE's strategic push for economic diversification and smart city development is creating significant demand for advanced construction and infrastructure solutions. This basket provides exposure to a selection of US and EU-listed companies that supply essential materials, technology, and engineering services to the region's projects.

UAE Infrastructure Global Suppliers Breakdown

UAE Infrastructure Global Suppliers Breakdown

As the UAE continues its ambitious economic diversification, demand for world-class infrastructure creates opportunities for the companies that build it. This basket offers exposure to US and EU-listed industrial, materials, and technology firms that are integral to developing these large-scale projects.

Antiviral M&A Wave: Biotech Opportunities in 2025

Antiviral M&A Wave: Biotech Opportunities in 2025

Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.

Frequently Asked Questions